Enzo Paoletti

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.

R. Siliciano, E. Paoletti, J. Mascola, 1998, The Journal of infectious diseases.

Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques.

E. Paoletti, J. Tartaglia, M. Robert-Guroff, 1996, AIDS research and human retroviruses.

Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques.

J. Tartaglia, M. Robert-Guroff, A. Abimiku, 1995, AIDS research and human retroviruses.

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

M. Kieny, J. Excler, T. Matthews, 1995, AIDS research and human retroviruses.

NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria

E. Paoletti, S. Hoffman, D. Smith, 1996, Infection and immunity.

Physical mapping and DNA sequence analysis of the rifampicin resistance locus in vaccinia virus.

E. Paoletti, J. Tartaglia, Enzo Paoletti, 1985, Virology.

Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160.

E. Paoletti, M. Kieny, J. Tartaglia, 1996, The Journal of infectious diseases.

Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein.

E. Paoletti, W. Cox, J. Tartaglia, 1993, Virology.

Role of the vaccinia virus E3L and K3L gene products in rescue of VSV and EMCV from the effects of IFN-alpha.

E. Paoletti, J. Tartaglia, B. Jacobs, 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Vaccinia virus rifampicin-resistance locus specifies a late 63,000 Da gene product.

E. Paoletti, J. Tartaglia, A. Piccini, 1986, Virology.

The safety and use of canarypox vectored vaccines.

E. Paoletti, J. Tartaglia, J. Excler, 1995, Developments in biological standardization.

Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC.

E. Paoletti, W. Cox, J. Tartaglia, 1994, Developments in biological standardization.

Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene.

R. Siliciano, E. Paoletti, J. Tartaglia, 1995, The Journal of infectious diseases.